Format

Send to

Choose Destination
BMC Cancer. 2018 Nov 6;18(1):1069. doi: 10.1186/s12885-018-4984-3.

The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study.

Author information

1
Epidemiology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
2
Department of Health, Emilia-Romagna Region, Bologna, Italy.
3
Epidemiology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy. venturelli.dr.francesco@gmail.com.
4
Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy. venturelli.dr.francesco@gmail.com.
5
Hematology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
6
Department of Diagnostics, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy.
7
Epidemiology Unit, AUSL of Modena, Modena, Italy.

Abstract

BACKGROUND:

Chronic myeloid leukemia is associated with a BCR/ABL oncoprotein inhibited by imatinib mesylate, the first tyrosine kinase inhibitor. Although experimental studies have clearly demonstrated the efficacy of imatinib, up-to-date data on its effectiveness at the population level are limited. Our study aims to assess the change in disease-specific survival for chronic myeloid leukemia after introducing tyrosine kinase inhibitors in first-line treatment.

METHODS:

This study analyzed data from two population-based cancer registries in Italy. Disease-specific survival for chronic myeloid leukemia cases diagnosed before and after the introduction of tyrosine kinase inhibitors (February 2002) were calculated up to 10 years. Hazard ratios were calculated using Cox regression models adjusted for sex, age at diagnosis and residency. An interrupted time series analysis was also performed.

RESULTS:

Between 1996 and 2012, 357 new cases of chronic myeloid leukemia were diagnosed (standardized incidence rate of 1.2 per 100,000 residents), quite constant throughout the period. The interrupted time series analysis showed a gain of 40.4% in 5 years of disease-specific survival for chronic myeloid leukemia (from 47.3, 95%CI 38.5-55.5% to 80.8%, 95%CI 74.5-85.8%) after the introduction of tyrosine kinase inhibitors. The hazard ratio was 0.36 (95%CI 0.25-0.52) for cases diagnosed after tyrosine kinase inhibitor introduction, with differences per age at diagnosis: <65yo 0.17 (95%CI 0.08-0.39), >74yo 0.41 (95%CI 0.23-0.73). An improvement in survival (hazard ratio 0.66, 95%CI 0.36-1.20) was also observed in cases diagnosed before, and alive at, tyrosine kinase inhibitors introduction.

CONCLUSIONS:

Tyrosine kinase inhibitors increased disease-specific survival both for new and prevalent chronic myeloid leukemia cases. The effectiveness was similar to that observed in trials only in patients ages 65 years or younger.

KEYWORDS:

Chronic myeloid leukemia; Imatinib Mesylate; Interrupted time series analysis; Population registers; Survival analysis

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center